Small molecule enhancers of endogenous lectins (like galectin-3) could specifically recognize altered glycan patterns on tau vesicles and direct them toward autophagosomal degradation. This would create a selective clearance pathway for pathological tau aggregates.
Auto-built from this analysis's top knowledge-graph edges.
graph TD
LGALS3["LGALS3"] -->|regulates| autophagy["autophagy"]
LGALS3_1["LGALS3"] -->|targets| tau_vesicles["tau_vesicles"]
LGALS3_2["LGALS3"] -->|modulates| autophagy_pathway["autophagy_pathway"]
LGALS3_3["LGALS3"] -->|enhances| autophagy_4["autophagy"]
style LGALS3 fill:#ce93d8,stroke:#333,color:#000
style autophagy fill:#4fc3f7,stroke:#333,color:#000
style LGALS3_1 fill:#4fc3f7,stroke:#333,color:#000
style tau_vesicles fill:#4fc3f7,stroke:#333,color:#000
style LGALS3_2 fill:#4fc3f7,stroke:#333,color:#000
style autophagy_pathway fill:#81c784,stroke:#333,color:#000
style LGALS3_3 fill:#ce93d8,stroke:#333,color:#000
style autophagy_4 fill:#81c784,stroke:#333,color:#000No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for LGALS3 yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LGALS3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF the carbohydrate recognition domain (CRD) of galectin-3 is required for tau clearance, THEN a CRD-mutant galectin-3 (R186S, critical for glycan binding) will fail to reduce pathological tau levels | Wild-type galectin-3 overexpression produces >35% reduction in tau aggregates; CRD-mutant produces <15% reduction (no different from empty vector) | — no observation — | pending | 0.35 |
| IF galectin-3 (LGALS3) is pharmacologically enhanced via small molecule activators or viral overexpression in primary neurons seeded with pathological tau aggregates, THEN phosphorylated tau (p-tau Se | At least 40% reduction in Sarkosyl-insoluble phosphorylated tau (Ser396, AT8-positive) measured by ELISA or immunoblot | — no observation — | pending | 0.45 |